Last reviewed · How we verify

Intravenous morphine and oral oxycodone

University of Puerto Rico · FDA-approved active Small molecule

Morphine and oxycodone are opioid agonists that bind to mu-opioid receptors in the central nervous system to reduce pain perception and provide analgesia.

Morphine and oxycodone are opioid agonists that bind to mu-opioid receptors in the central nervous system to reduce pain perception and provide analgesia. Used for Moderate to severe acute pain, Moderate to severe chronic pain.

At a glance

Generic nameIntravenous morphine and oral oxycodone
SponsorUniversity of Puerto Rico
Drug classOpioid analgesic
TargetMu-opioid receptor (OPRM1)
ModalitySmall molecule
Therapeutic areaPain management
PhaseFDA-approved

Mechanism of action

Both morphine and oxycodone work by activating mu-opioid receptors throughout the brain and spinal cord, which modulates pain signal transmission and produces analgesic effects. Morphine is administered intravenously for rapid onset in acute or severe pain settings, while oxycodone is given orally for sustained pain management. Together, they represent a multimodal opioid approach to pain control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: